檢索結果 - Jamie Geier

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Chromosomal position of a V(H) gene segment determines its activation and inactivation as a substrate for V(D)J recombination

    Chromosomal position of a V(H) gene segment determines its activation and inactivation as a substrate for V(D)J recombination 由 Bates, Jamie Geier, Cado, Dragana, Nolla, Hector, Schlissel, Mark S.

    出版 2007
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  2. 2
    Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

    Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist 由 Christina Charles‐Schoeman, Miguel Á. González‐Gay, Irina V Kaplan, M. Boy, Jamie Geier, Zhen Luo, Andrea Zuckerman, Richard J. Riese

    出版 2016
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Completed and Attempted Suicides Among 18,154 Subjects With Schizophrenia Included in a Large Simple Trial

    Completed and Attempted Suicides Among 18,154 Subjects With Schizophrenia Included in a Large Simple Trial 由 W. Wolfgang Fleischhacker, John M. Kane, Jamie Geier, Onur N. Karayal, Sheela Kolluri, Sybil M. Eng, Robert F. Reynolds, Brian L. Strom

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

    Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme 由 Jeffrey R. Curtis, Eun Bong Lee, Irina V Kaplan, Kenneth Kwok, Jamie Geier, Birgitta Benda, Koshika Soma, Lisy Wang, Richard J. Riese

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

    Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor 由 Christina Charles‐Schoeman, Pierre Wicker, Miguel Á. González‐Gay, M. Boy, Andrea Zuckerman, Koshika Soma, Jamie Geier, Kenneth Kwok, Richard J. Riese

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

    Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials 由 Vibeke Strand, Sima Ahadieh, Jonathan French, Jamie Geier, Sriram Krishnaswami, Sujatha Menon, Tina Checchio, Thomas G. Tensfeldt, Elaine Hoffman, Richard J. Riese, M. Boy, Juan J. Gómez‐Reino

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis

    Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis 由 Megan E. B. Clowse, Steven R. Feldman, John D. Isaacs, Alexa B. Kimball, Vibeke Strand, Richard B. Warren, Daniel Xibillé, Yan Chen, Donald E. Frazier, Jamie Geier, James Proulx, Amy Marren

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

    Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials 由 Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard J. Riese, J. Wollenhaupt

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

    Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry... 由 Joel M. Kremer, Clifton O. Bingham, Laura C. Cappelli, Jeffrey D. Greenberg, Ann Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea Shapiro, Carol A. Connell, Arthur Kavanaugh

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: